| Dr Sana Ghafoor, MD | |
|
549 Fair St, Bloomsburg, PA 17815-1419 | |
| (570) 416-1867 | |
| (570) 416-1848 |
| Full Name | Dr Sana Ghafoor |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Neurology |
| Location | 549 Fair St, Bloomsburg, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770870396 | NPI | - | NPPES |
| Entity Name | Geisinger Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366493868 PECOS PAC ID: 5395657001 Enrollment ID: O20040130000518 |
News Archive
HealthPort, a top-25 company in the healthcare information technology industry, today announced that it is providing a money-back guarantee that its Electronic Health Record (EHR) software, HealthPort EHR, will meet certification requirements for Meaningful Use as set forth in the American Recovery and Reinvestment Act (ARRA) of 2009.
The gap in stillbirth rates between indigenous and non-indigenous women in Queensland, Australia, is closing, however indigenous women are still at risk of stillbirth due to preventable causes, find researchers in a new study published today (3 September) in BJOG: An International Journal of Obstetrics and Gynaecology (BJOG).
Gerresheimer AG, one of the leading worldwide suppliers to the pharma and healthcare industry, remained on its growth path during the second quarter of the financial year 2010. "Our business developed very well in the second quarter. The demand for our products in the pharma industry has grown and there has also been an improvement recently in the Cosmetics and Life Science Research businesses," says Uwe Rohrhoff, the new CEO of Gerresheimer AG since June 22, 2010.
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention. The paper will be published May 15 in Cancer Research.
Palatin Technologies, Inc. today announced that the U.S. Food and Drug Administration has cleared Palatin's request to begin a Phase 2A proof-of-concept human trial under an Investigational New Drug application using a subcutaneously administered formulation of PL-3994, an NPR-A agonist compound, in development for treatment of acute exacerbations of asthma.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sana Ghafoor, MD 100 N Academy Ave, Danville, PA 17822-4903 Ph: (570) 214-9907 | Dr Sana Ghafoor, MD 549 Fair St, Bloomsburg, PA 17815-1419 Ph: (570) 416-1867 |
News Archive
HealthPort, a top-25 company in the healthcare information technology industry, today announced that it is providing a money-back guarantee that its Electronic Health Record (EHR) software, HealthPort EHR, will meet certification requirements for Meaningful Use as set forth in the American Recovery and Reinvestment Act (ARRA) of 2009.
The gap in stillbirth rates between indigenous and non-indigenous women in Queensland, Australia, is closing, however indigenous women are still at risk of stillbirth due to preventable causes, find researchers in a new study published today (3 September) in BJOG: An International Journal of Obstetrics and Gynaecology (BJOG).
Gerresheimer AG, one of the leading worldwide suppliers to the pharma and healthcare industry, remained on its growth path during the second quarter of the financial year 2010. "Our business developed very well in the second quarter. The demand for our products in the pharma industry has grown and there has also been an improvement recently in the Cosmetics and Life Science Research businesses," says Uwe Rohrhoff, the new CEO of Gerresheimer AG since June 22, 2010.
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention. The paper will be published May 15 in Cancer Research.
Palatin Technologies, Inc. today announced that the U.S. Food and Drug Administration has cleared Palatin's request to begin a Phase 2A proof-of-concept human trial under an Investigational New Drug application using a subcutaneously administered formulation of PL-3994, an NPR-A agonist compound, in development for treatment of acute exacerbations of asthma.
› Verified 4 days ago
David J Shiling, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 549 Fair St., Bloomsburg, PA 17815 Phone: 570-416-1867 | |
Nancy Kelley, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 549 Fair St, Bloomsburg, PA 17815 Phone: 570-416-1867 Fax: 570-416-1848 |